Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
- Conditions
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 140
- Registration Number
- NCT05178745
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
- Conditions
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 14
- Registration Number
- NCT05179603
- Locations
- 🇨🇱
Investigational Site Number : 1520002, Santiago, Reg Metropolitana De Santiago, Chile
🇨🇱Investigational Site Number : 1520004, Vina del Mar, Valparaíso, Chile
🇨🇱Investigational Site Number : 1520001, Temuco, Chile
BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 45
- Registration Number
- NCT05156710
- Locations
- 🇺🇸
Harvard Medical School - Massachusetts General Hospital (MGH) - Medical Practice Evaluation Center (MPEC)- Site Number : 8400007, Boston, Massachusetts, United States
🇺🇸Cedars-Sinai Medical Center- Site Number : 8400100, Los Angeles, California, United States
🇺🇸University of California Los Angeles Medical Center- Site Number : 8400103, Los Angeles, California, United States
Efficacy and Safety of FIRTECH in Patients With Mild to Moderate Acute Low Back Pain
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 221
- Registration Number
- NCT05137041
- Locations
- 🇮🇹
Investigational Site Number :5, Alessandria, Italy
🇩🇪Investigational Site Number :01, Munich, Germany
🇮🇹Investigational Site Number :7, Taormina, Messina, Italy
Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 6
- Registration Number
- NCT05132569
- Locations
- 🇨🇳
Investigational Site Number :1560003, Chengdu, China
🇨🇳Investigational Site Number :1560001, Shanghai, China
🇨🇳Investigational Site Number :1560002, Wuhan, China
Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 7
- Registration Number
- NCT05132127
- Locations
- 🇯🇵
Investigational Site Number 3920003, Osaka, Japan
🇯🇵Investigational Site Number 3920002, Saitama, Japan
🇯🇵Investigational Site Number 3920001, Tokyo, Japan
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity
- Conditions
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3
- Registration Number
- NCT05128773
- Locations
- 🇨🇳
Investigational Site Number :1561599, Haikou, China
🇨🇱Investigational Site Number :1521622, Santiago, Reg Metropolitana De Santiago, Chile
Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 163
- Registration Number
- NCT05129241
- Locations
- 🇩🇪
Investigational Site Number, Germany, Germany
Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 13
- Registration Number
- NCT05126329
- Locations
- 🇩🇪
Investigational Site Number :2760001, Kiel, Germany
🇰🇷Investigational Site Number :4100001, Seoul, Seoul-teukbyeolsi, Korea, Republic of
🇰🇷Investigational site number :4100002, Cheongju-si, Korea, Republic of
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 124
- Registration Number
- NCT05114590
- Locations
- 🇺🇸
Downtown LA Research Center Inc - ClinEdge - PPDS-Site Number:8400001, Los Angeles, California, United States
🇺🇸University Clinical Investigators Inc-Site Number:8400020, Tustin, California, United States
🇺🇸Floridian Research Institute-Site Number:8400013, Miami, Florida, United States